BFLY

Hello everyone, thank you for joining the Butterfly Network Inc Q1 2026 Earnings Call. My name is Gabrielle and I will be coordinating your call today. During the presentation, you can register a question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two on your telephone keypad. I will now hand over to your host, John Doherty. Please go ahead.

Good morning, thanks to all of you for joining our call today. Earlier, Butterfly released financial results for the first quarter ended March 31st, 2026. We also provided a business update. The release, which includes a reconciliation of management's use of non-GAAP financial measures compared to the most applicable GAAP measures, is currently available on the investors section of the company's website at ir.butterflynetwork.com. I, John Doherty, Chief Financial Officer of Butterfly, along with Joseph DeVivo, Butterfly's Chairman and Chief Executive Officer, will host the call this morning. During today's call, we will be making certain forward-looking statements.

These statements may include, among other things, expectations with respect to financial results, future performance, development and commercialization of products and services, potential regulatory approvals, revenue attributable to embedded partnerships through revenue share, ship purchases or otherwise, and the size and potential growth of current or future markets for our products and services. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our filings made with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligation to update such statements. As a reminder, this call is being webcast live and recorded.

To access the webcast, please visit the events section of our investor website. A replay of the event will also be available on this page following the call. I would now like to turn the call over to Joe.

Thanks, John. Before I begin, I want to take a moment to congratulate our board member, Dr. Erica Schwartz, on her nomination to serve as this country's CDC Director. The entire Butterfly family is proud of her, and we remain grateful to have her as a valued member of our board. We've been so fortunate to benefit from her insight, leadership, and friendship for the past five years. She has certainly contributed to where Butterfly is today. With that, I'm pleased to welcome you to our first quarter call this year and to share that we've been making real progress across every facet of our business. Our plan to become the leader in clinical ultrasound is firmly established, and the market is moving towards a system-wide understanding of the power Butterfly can grant. Butterfly opened 2026 with another strong financial performance.

25% revenue growth, 69% gross margin, and the lowest first quarter net loss since going public, all while maintaining a very strong balance sheet to support future growth. This performance shows our momentum regardless of the environmental noise, and it's an indicator of what's ahead as we continue to make meaningful progress across every phase of our business. I'm excited to walk you through our updates. Butterfly is in the middle of the digital transformation of imaging driven by the power of semiconductors and ultrasound. We are beginning to experience the convergence of massive computational power, artificial intelligence, and the incredibly customizable digital visualization, which can disrupt not only imaging and healthcare, but far beyond. We are living through a profound moment of technological acceleration, one that healthcare has been waiting for.

The merge of intelligence with the human body through smart ultrasound form factors that can live with every person everywhere. It starts with our core focus business, empowering every doctor and nurse with a powerful digital imaging device connected to an ecosystem of AI applications, education, and data to deliver immediate clinical care wherever the patient is in the world. We are excited to be the first company ever to earn FDA clearance of a blind sweep AI tool, which in two minutes can determine the age of a fetus. You may have seen this circulating on either LinkedIn or X, but we were very proud that the FDA itself highlighted our clearance publicly on social media as a meaningful demonstration of their increased focus on AI-enabled technologies and how to do it correctly in partnership with them.

I've reposted it if you wanna go to my account and find it. The GA Tool is a true reflection of our mission. Each year, millions of women around the globe enter pregnancy without a reliable way to determine gestational age. In global, rural, or emergency settings, patients often enter care not knowing key dates due to lack of prior prenatal care or are unable to verbalize them due to their condition. Without accurate gestational age, clinical decision-making becomes more complex as each stage of pregnancy requires different treatment pathways. Now, clinicians can determine gestational age quickly and with a high degree of accuracy using our GA Tool that's built on deep learning models from Dr. Jeffrey Stringer's team at the University of North Carolina and trained on over 21 million images.

Butterfly is now in the process of launching this tool to those who need it most in the U.S. and many global health settings that rely on FDA regulatory pathways. Moments like this demonstrate the strength of Butterfly's architecture. With a single cloud-based software update, similar to how a smartphone is updated, we can push this capability to existing users anywhere cleared in the world. The GA Tool is expected to unlock new relationships with ministries of health across developing countries, moving beyond the idea of democratizing healthcare to actually delivering on it. AI applications that give local caregivers access to advanced diagnostics will be the most powerful accelerator of handheld point-of-care ultrasound. Whether developed internally or through our partners in the Butterfly Garden, these applications can make the complex simple and expand access to patients in highly scalable and cost-effective ways.

This quarter, two new partners joined to develop in the Butterfly Garden, bringing the portfolio total to 30. Four of our existing partners have received FDA clearance for versions of their software. Most recently, DeepEcho received breakthrough designation from the FDA and expects clearance of a robust prenatal AI application potentially by the end of this year. We anticipate iCardio going live with an FDA-cleared model this year, beginning of next year as well. We are very pleased with the progress HeartFocus is making following its launch of a clinical app late last year. We believe all of these applications, combined with Butterfly's internally developed capabilities, will become the largest, most powerful AI-powered ultrasound library in the industry. Over the next three years, we expect this to drive a meaningful inflection in probe utilization and overall system adoption.

Continuing with focus, our Compass AI launch last quarter is showing early success. Our pipeline of software deals measured in total contract value is up sharply from the first quarter of 2025, serving as an early indicator of meaningful enterprise adoption in 2026. We have already closed our first enterprise deal this quarter and are seeing strong momentum, including a seven-figure software TCV deal with a customer committing to the long-term Compass AI roadmap. In addition, medical schools are accelerating one-to-one adoption with nearly 1,000 probes sold so far this year across six institutions and more programs coming online.

These efforts are supported by continued advancement of our already robust enterprise security posture, with recent milestones including HITRUST r2 certification and entry into the FedRAMP marketplace as in process with VA sponsorship, further enhancing our ability to support large health systems and expand into federal opportunities. Over the next few quarters, we expect to further the global scale of our POCUS business, continuing to open multiple new markets across the Americas and Asia, including some of the largest and fastest-growing POCUS markets like Brazil. At the same time, we've been working to expand iQ3 availability to over a dozen additional countries already in our regulatory pipeline. Moving to Home. Now officially named Butterfly Home and Community Care, we are making important progress.

We expect now our first commercial agreement to be signed in the first half of this year and begin training nurses to support patient scanning across our full state in the third quarter. We believe this model can expand significantly across the United States in 2027 and represents a foundational shift in how care is delivered. It enables Atlas providers to take control of patient outcomes with AI-powered diagnostics, reducing unnecessary hospital visits and improving system efficiency. I am very proud of our team for maintaining their focus and skilled execution in building this business. Lastly, I'd like to briefly update you on our efforts regarding the RoHS lead exemption for handheld ultrasound. We filed an application to revoke this exemption last year, which currently allows the continued use and disposal of toxic materials in lead-based piezo crystal handheld ultrasound in the EU.

The commission engaged a third party named Oeko to review the exemption request and make a recommendation. Through this process, they confirmed CMUT to be a technically viable alternative, meaning they have met or exceeded the capability of incumbent technologies. Oeko ultimately recommended reapproval of the exemption, only for two years. This is important because exemptions can typically span anywhere from two to seven years. Therefore, Oeko opted to recommend the lowest possible term for an exemption following its review of our request. We believe that during these two years, the EU will gain the understanding they need to revoke the lead exemption for handhelds, including greater awareness, viable alternatives to piezoelectric crystals in handheld ultrasound devices, and clarity that replacing piezo handhelds will not present an impediment to healthcare delivery, rather introduce a more digital and more effective delivery of medicine.

We understand the complexity of disrupting established industry practices, but believe the EU has gained significant insights into the existence of a viable alternative and meaningful progress is being made. I'll save our Embedded update for after John's comments and would now like to turn it over to John. John?

Thanks, Joe. Butterfly continued its solid and focused execution in the first quarter of 2026, with an increase in revenue driven by double-digit growth in both our core and embedded businesses, an increase in gross margin, and continued improvement in operating performance with further reallocation of resources towards higher ROI opportunities and markets. Let me touch on a few highlights in the quarter that demonstrate this, including revenue attainment that was above consensus, continued gross margin improvement, adjusted EBITDA that was above consensus and our guidance range with improvement driven by our revenue performance, higher gross margin and continued financial discipline. Growth in probe sales of 5% and an increase in the mix of iQ3 devices, driving an 11% improvement in ASP year-over-year. The expansion of the Butterfly Garden platform, as well as the inclusion of the GA Tool in our latest software update.

Execution of a large seven-figure TCV Compass AI contract with a growing pipeline in this area that Joe mentioned upfront. The expected commercial launch in an initial state with a major U.S. direct care provider to support in-person, virtual, and in-home healthcare services. With that, let me move on to our results. We started the year strong, with revenue of $26.5 million, an increase of 25% year-over-year. Our growth was primarily driven by strength in our U.S. health, international, and vet channels, a higher mix of sales of the iQ3 year-over-year, driving a higher ASP and from Butterfly Embedded.

Breaking things down between the U.S. and international channels, during the first quarter, U.S. revenue was $21.4 million, which was 25% higher year-over-year, driven by revenue from Embedded, as well as solid demand in the core business, with unit sales up 5% in what is typically a slower quarter due to seasonality. Total international revenue increased by 23% year-over-year to $5.2 million in the quarter. While sales of the iQ3 in the quarter were up 39% year-over-year, sales of the lower priced iQ+ were down 43%, driving the increase in ASP. With the increasing contribution from Embedded, today and going forward, I'm gonna provide you with a revenue split between our core business and Butterfly Embedded. We have also included this split in our 10-Q.

The core business includes probe sales and related software, Compass AI, other services, and in the future, home. Embedded revenue currently includes one-time NRE payments, annual license fees, revenue from SOW-driven development work, and chip sales to Embedded partners. With that, core revenue for the first quarter was $20.8 million, an increase of 10% versus the first quarter of 2025. This increase was driven by growth in volume and price with a higher mix of iQ3 sales, with strength in U.S. health, international, e-com, and vet. Butterfly Embedded revenue was $5.7 million, an increase of 147% versus the first quarter of 2025. This increase was primarily driven by the Midjourney partnership. Moving on to gross profit.

Gross profit was $18.3 million in the first quarter, a 37% increase as compared to the prior year gross profit of $13.4 million. Gross profit margin percentage increased to 69% from 63% in the prior year period, an increase of 9%. Gross margin percentage was positively impacted by the higher margin Butterfly Embedded revenue and the higher mix of iQ3 and its higher selling price, along with lower software amortization. Moving to EBITDA and cash. For the first quarter of 2026, adjusted EBITDA loss was $6.1 million, compared with a loss of $9.1 million for the same period in 2025, an improvement of 32%. The improvement in adjusted EBITDA loss in the first quarter was driven by contribution from higher margin revenue and continued financial discipline.

Our cash and cash equivalent balance, excluding restricted cash, at the end of the first quarter was $138 million, and the use of cash in the quarter was $12.5 million. This compares to a use of cash of $14.7 million in the prior year quarter, an improvement of $2.2 million or 15%. These results continue to demonstrate that we are very well positioned as we move forward to continue to invest in the business in areas where we see significant opportunities for additional growth and disruption, including expanding our POCUS business and penetration of Compass AI as a core operating system for health systems, empowering third-party development through Butterfly Garden to accelerate adoption of our platform.

Expanding our Home and Community Care business into its commercial phase. Enabling a new wave of ultrasound on chip technologies through Butterfly Embedded, and continuing AI and semiconductor innovation with the development of our fourth generation chip. Before turning to guidance, I want to update you on the global macroeconomic environment relative to Butterfly. We continue to monitor the war in the Middle East and the ripple effects on the global economy, as well as tariffs in certain markets. While there are some impacts to our business, they have been minor, and we continue to manage through it and make the appropriate adjustments. Our first quarter 2026 results are indicative of this, and our second quarter and full year 2026 guidance include any expected impacts.

I would now like to turn to our outlook for the second quarter of 2026 and for the calendar year ending December 31st, 2026. In the second quarter, we expect revenue in the range of $27 million-$31 million, or a year-over-year increase of 24% at the midpoint. We expect an adjusted EBITDA loss in the range of $6 million-$8 million. For the full year 2026, we are reaffirming our guidance for both revenue and adjusted EBITDA. We expect revenue to be between $117 million and $121 million, an increase of approximately 20%-24% over 2025. We expect our adjusted EBITDA loss to be between $21 million and $25 million.

As I mentioned previously, our guidance for adjusted EBITDA in the second quarter and full year includes increased investment in key areas to support continued innovation and revenue growth in our core business and our emerging Embedded business for 2026 and beyond. In summary, we had a strong start to 2026. We came in above the midpoint of our revenue guidance, and we beat our adjusted EBITDA guidance. We believe we are very well positioned for the balance of 2026. As our 2026 full year guidance indicates, we look forward to continued growth this year and beyond. Our overall outlook on the business is positive, with the first quarter reinforcing our view. We continue to be focused on gaining share in 2026 through deeper penetration of existing customers, new customers and applications.

We also continue to be focused on enhancing our existing and developing new partnerships leveraging our ultrasound on chip platform. We continue to be excited about the potential of Butterfly Embedded and our licensing and related revenue opportunities. The business is getting stronger, with core focus generating new revenue opportunities in addition to probe sales through Compass, Garden, and Home and the potential of Butterfly Embedded. This is happening while we continue our intense focus on driving operating efficiency across the business and return on investment. I continue to be excited about what is ahead for the company in 2026 and beyond. Let me hand it back to Joe for some closing comments.

Thanks, John. Ultrasound has many use cases which are growing rapidly in both scientific and clinical importance.

As I mentioned last quarter, if you scan publications in Nature over the past year, you'll find a body of literature growing around functional ultrasound. These applications are ranging from neural imaging and brain computer interfaces, biosensing and targeted drug delivery to wearable monitoring and autonomous robotic procedures, just to name a few. What was once a diagnostic modality is aspiring to become something far more powerful. It's becoming a dynamic interface with biology itself. As I mentioned at the start, what is driving this shift now is a convergence of massive computational power, artificial intelligence, and a new class of digital imaging systems. For the first time, imaging is no longer static. It's becoming adaptive. It's becoming intelligent. It's beginning to learn. There is only one company in the world that has commercialized ultrasound at scale through a fully digital semiconductor-based system that is infinitely programmable. That's Butterfly.

A traditional piezoelectric crystal, well, they're fixed. They transmit and receive in a fixed way. Our digital ultrasound is fundamentally different. It can transmit and receive signal, interpret what it sees through powerful compute and AI, and immediately adjust how it transmits and receives again. It creates a closed-loop system where sensing, thinking, and acting are happening continuously in real time. This is the beginning of imaging systems that do not just observe the human body, but will integrate into it. Over time, these systems will move from episodic use into continuous presence, embedded into workflows, into devices, and eventually into everyday life. This is where imaging, computation, and biology converge into something entirely new. Butterfly is at the center of this convergence, which is becoming increasingly evident in the brain-computer interface space.

Our chip is uniquely well-suited for this application, given their programmable architecture, ability to both transmit and sense with precision, and tight integration with software, compute, and AI. This is exactly where our Apollo platform is headed. By extending this foundation, we are building a platform that combines the ability to image and stimulate through software and enable new classes of applications beyond traditional handheld imaging. We are investing strategically in the talent, the partnerships, and the platform to lead in this new category through Butterfly Embedded, which we introduced last quarter as a rebrand of [Oculus]. Embedded is being led by Dr. David Horsley, a proven innovator in MEMS and semiconductor systems, and we are furthering our engineering and commercial capabilities required to engage with the most important technology platforms in the world.

Establishing the embedded business with intentions of building a team in San Francisco is a critical step in extending our platform into the broader technology ecosystem. The early traction in embedded is very promising. We signed our ninth partner this month and expect to add at least two more mid-year. These are not just incremental relationships. They represent the early formation of a new market where ultrasound becomes a native capability inside other systems. We are just getting started. Speaking of transformative platforms, we are very excited about the progress we are making with Midjourney and look forward to them unveiling their solution when they are ready. It is clear to us today that the Apollo chip will be a major catalyst of revenue growth for Butterfly.

Not only will it usher in the next wave of AI in image processing and enhancement, as well as on-device AI compute for POCUS. Our partners want the processing speed it will provide given the massive amount of data they intend to generate. As I mentioned, not only will Apollo have the more powerful MEMS elements that enable harmonic imaging, it'll be able to process 20 times the data of the chip that we will launch next year, P5.1. This new architecture is being designed into very sophisticated future systems that stream real-time ultrasound data straight into the GPU memory, providing the ability to process a massive amount of image data far exceeding today's standards. We also have identified versions of the Apollo architecture which can be modified to meet some of the largest future use cases known today.

When you step back and look at Butterfly today, you see three engines of growth that are beginning to reinforce each other. Chronic care ultrasound is scaling across health systems globally. Home and Community Care is expected to extend that capability directly into the patient environment, changing how care is delivered and paid for. Embedded extends Butterfly beyond standalone devices by integrating ultrasound as an AI-enabled sensing platform into entirely new applications across healthcare and adjacent markets. Together, these are not separate businesses. They are all playing a key role in leveraging our unique ultrasound on-chip ecosystem. Over the next three years, we are not just expecting growth. We are entering a period of transformation. As these systems mature and converge, they will unlock new behaviors, new standards of care, and entirely new markets that do not exist today.

What has historically been episodic, expensive, and limited will become continuous, intelligent, and broadly accessible. We believe this shift will fundamentally change how the world interacts with imaging, with healthcare, and ultimately with the human body itself. Over the next three years, we expect this convergence to materially expand our addressable market and drive a step change in utilization, which we believe will be reflected directly in revenue growth and operating leverage. This is the moment where decades of scientific progress meet the scale of modern compute and the power of artificial intelligence. When that happens, change does not move linearly. It moves exponentially. We believe Butterfly can become the default imaging and sensing layer for the human body. Butterfly's positioned at the center of this shift.

Importantly, we are building this with discipline, maintaining the strength of our balance sheet so our investors can fully participate in the value creation ahead. This call marks my third anniversary with Butterfly. The last two years were focused on building a framework for success and the foundation to execute. The next three years are about running fast, scaling revenue into the future, and being the company to enjoy the full potential of what we've built. We are in a new era where imaging becomes intelligent, adaptive, and ever-present, where it moves closer to the patient, becomes part of everyday care, and ultimately becomes part of everyday life. We are incredibly excited about what lies ahead. This is only the beginning. With that, operator, please open it up for questions.

Thank you. To ask a question, please press star followed by one on your telephone keypad now. If you change your mind, please press star followed by two. When preparing to ask a question, please enter your device. Our first question is from Chase Knickerbocker from Craig-Hallum Capital. Your line is now open. Please go ahead.

Good morning. This is Jake Soucheray for Chase. Thanks for taking the questions.

Good morning, Jake.

Morning. It seems like the one-to-one partnerships are going well. Can you speak to any progress made with the med schools so far in the second quarter and how that compares to prior years?

Well, the second quarter is happening right now. Usually, the second quarter is our biggest medical school quarter, given that their fiscal year ends on June 30th. Yeah, I mean, this is, you know, we had a good first quarter with medical schools. We'll have a very good quarter in the second quarter with medical schools. The key for us is continuing the momentum to convince them that every student when they come in should have their own probe. There are 100,000 medical students, you know, in the United States, 25,000, you know, enroll every year. You know, that is an opportunity if it extended to every school of, you know, doubling the amount of probes we sell every year.

We have, you know, very good relationships. We just had, weeks ago, the AACOM meeting with, you know, a lot of people participating in our luncheon, or AACOM, I mean, e-meeting. The relationships, the momentum is all growing. I'd expect our medical school activity to be very positive in the second quarter.

Thanks for that color. Then I'd like to hear some more color on the Compass AI enterprise deal. How did that process go? Can we expect more of these partnerships materially contributing to revenue in the rest of the year?

Yeah. As I said in the prepared remarks, we... Our pipeline has, like, clicked up. It's, I think the word in the script was it was a sharp increase. We've seen a lot of activity, a lot of receptivity in the innovation that we've brought to the platform, plus just the general market building. Our pipeline's up pretty big. If the pipeline's up pretty big, then that's an indicator the enterprise sales will follow. I'd expect this to be a very good enterprise year. I'd expect this to be a very good Compass AI year. I think we hit the mark with making this easier for clinicians, faster to document. There's a lot of other tools that we're building. Very good start.

Thanks for taking the questions.

No problem. Thanks for asking.

Thank you. Our next question is from Josh Jennings from TD Cowen. Your line is now open. Please go ahead.

Good morning, Joe and John. Thanks for the questions, and congratulations on the strong start to the year. Exciting times. Appreciate the download, and Joe, you sharing your enthusiasm on all the progress and the future. Wanted to ask about Butterfly Embedded. It's nine companies in the portfolio. It sounds like there may be other partnerships on tap. I don't know if there's any way to help us think about the pipeline and any qualitative or quantitative help thinking about it, just in terms of, I mean, or should we be thinking that there are more Midjourney-type deals on tap? A mix, any more color on that embedded, you know, partnership portfolio and pipeline would be great to hear.

No, that's a great question, Josh. It's good to hear from you. Thank you. I guess the way I'd put it is every time we add a partner, we're adding the opportunity of developing an entirely new market segment. An entirely new market segment where we are embedding our technology and their technology. They have a vision to be able to go and grow and invest. Each new partner is an opportunity to create significant leverage for Butterfly. It really depends upon where the stage of the idea is and the, you know, and where the stage of the company is. These companies are developing these new technologies. They also wanna keep it secret.

You know, they're not looking to, they're not looking to give breadcrumbs to their competitors. They're looking to do their development. It is a very delicate balance for us where, you know, we're a public company. We need to be able to communicate our progress. We try to do the best we can, you know, to frame the progress to give you the understanding of what's happening without creating any trust, you know, from our partners. I mean, even the Midjourney deal, as we discussed, was never announced. Never a press release. We had to do an 8-K 'cause it was a material deal. They wanna be able to announce and communicate when they're ready.

What I will say, 'cause I know what you're getting at, is you're asking if any one of these deals that we are working on could potentially have the financial impact in the near term that a Midjourney deal could have. I would say yes. You know, we are working on opportunities that could present similar type of near-term. I think, you know, each one of these are different. Each of them are different companies, different markets, and different phases. Sometimes a company comes in and they, you know, they don't wanna invest this type of work unless they, you know, have the opportunity to be exclusive in their area. The exclusivity is what they're paying for. I would say yes, there are conversations that we are having that could replicate a Midjourney type of transaction.

Appreciate that. Maybe a follow-up just on the update on the Home and Community Care channel, commercial agreement first half. The initial statewide deployment in 3Q. I was hoping to better understand, you know, your vision of or how you envision this playing out. I mean, is the initial statewide deployment have a commercial pilot and then build from there? Or how should we be thinking about the contributions from that Home and Community Care channel state by state over the next six, 12, 24 months? Thanks again for taking the question.

No, no problem. It's a very good question again. As we had communicated in the past, we had conducted a pilot, and it was, let's call it more of a feasibility pilot where our partner wanted to see if this would work. As we communicated in the past, I think there was about 100 patients that went through the protocol, and we saw a meaningful reduction of admissions and readmissions into the hospital. We were able to, you know, in that feasibility work, show that this conceptually could be very valuable. Now we're onto the next phase, which is our first commercial agreement.

If we get everything done, which we expect will now, with the activity in place, be done by the first half of the year. That'll have us now operating with the teams commercially. Instead of just into a controlled pilot, it would be into a real-world setting, where there would be education, there would be daily interaction through our platform, there would be the ability to measure outcomes. If that commercial, the initial commercial stage, continues to show the type of economic benefit that the initial pilot phase, it's only logical to believe that we would expand through more states, we would expand throughout the entire country. That's what our goal is for 2027.

For 2026, we wanna get the first state up and running. We wanna show this is operational. We wanna show this is incremental. We wanna show this is profitable. We wanna show it's better for patients. You know, the, the overlying narrative here by teaching nurses who are at the bedside caring for these patients every day how to use AI to help do a scan that they were not classically trained to do, but to do a scan that now allows for a specialist to give expert opinion to that patient where they are is a completely disruptive new model.

You know, the alternative is just simply waiting until they get sick enough where you have to send an ambulance to the skilled nursing facility, transport them to the hospital, wheelchair them up to radiology, do a cardiac echo, get them into the hospital, give them diuretics, monitor them, and then send them back home. send them back to the facility via that same ambulance that brought them there. That is not an inexpensive, that is not efficient, and that is not welcoming to our healthcare system or what is best patient care.

Being able to have that expert cardiologist opinion to happen real time, to have the data extracted real time, to allow a lower cost care professional to capture that image and be able to get that opinion within 24 hours and change the care for that patient and dial them in better, faster, is a significant reduction in the overall cost of healthcare. It's just the beginning 'cause we're talking now about managing congestive heart failure patients. What about patients with bladder infections? Well, we can do 3D bladder scans right then and there. They can do one after the other while they're with the patient. With all these new AI tools we're talking about, there's a flywheel here. You know, now, for example, they can test for a deep vein thrombosis.

They can test for a pleural effusion. There's all different types of things. Now, this is not just about creating a single revenue line in these facilities. It's about accelerating the evolution of handheld ultrasound at the patient's bedside by not just selling a probe, but by teaching them how to perform the application and being there with them, and creating the linkages between them and expert clinical care, and then being there to also measure those outcomes. This is a very, very big deal because what this will do is help accelerate the flywheel of adoption and in its core. I'd expect to see some revenue contribution in the second half of 2026.

I'd expect us to be successful, and I expect us to go more and more states and then to start build revenue in a very positive growth in 2027.

Thanks, Joe.

Thank you, Josh. Our next question.

Thanks, Josh.

is from Andrew Brackmann from William Blair.

Hey, guys. Good morning. Thanks for taking the questions. Maybe just to follow up.

Yeah, Andrew.

... to Josh's first question. Hey, Joe. Just wanna follow up to Josh's first question. Can you maybe just sort of talk to us about the life cycle for the Embedded partnerships? Just how do these typically start? When's that aha moment? I guess from your vantage point, what's your visibility look like throughout all these phases, visibility into sort of their ultimate use case and how big these could potentially be for you longer term?

I'll do the best I can for that one. Right now, up until three months ago, we have been simply getting inbounds. We have people who are looking for solutions. They understand that we have a chip. They've bumped into our intellectual property. They call us and they ask us, you know, consider working with them. I think I mentioned before, but we have over, you know, 40 companies that we are actively speaking to, and they're in a bunch of different markets. You know, it's in pharma, it's in BCI and neuromodulation, it's in robotics and surgical robotics. It's in HIFU. It's in organ preservation. It's in all these different markets where, you know, they're already working with some level of ultrasound, but kinda have a closed loop system. They want a system that can learn.

Also wearables and monitoring in a lot of different clinical variations are being investigated. Some of these are startup companies who, you know, just got their funding. Some of them are larger companies who are looking to add this into their product portfolio. Each of them have their different timelines. They come to us and then they wanna understand integrate with computational systems. How fast can they get the data? How fast can they process the data? Where could they process the AI?

Because a lot of this has to do with pulling data out of the body, processing that data, and then making clinical decisions, or even using the ultrasound to continue to get data, to continue to refine it, and then even, you know, provide therapy through the ultrasound or additional diagnostics. This is very, very complicated systems, and it's unbelievably exciting. It's all being based upon this new, you know, mass computation and also the intelligence of AI. You know, classic ultrasound systems cannot modify and modulate in real time.

You know, if you have a lens that is cut to see near on a camera, say, no matter what you do with your digital, no matter what you do with your energy, when you push it through that glass lens, it's going to only see near. With Butterfly, you can look, you can learn, and then it's almost like you're asking another question through ultrasound, and you can change how you ask that question. You can change how you modulate it. You can change the array. You can toggle from 2D to 3D. You can scan, you can slice. What we do is when partners come to us and say, "Well, we're really interested," the first thing they do is they give us a set of parameters.

They say, "Look, we're trying to get this frequency, this array, or in this location. You know, can you do it?" We say, "Depending upon those parameters, we will answer that question." If the question is favorable, we then go into a laboratory setting, and we show them how, you know, we can tune the ultrasound. We show them how we can get close to their use case or get to their use case with tuning the chip. It's kind of like just putting a program on a TV screen. You know, it's just we just reprogram it, and then it goes.

When we prove to them that we're either there or close to there, then that determines the next phase, which is, you know, what does it take to get the product and the software to be exactly the way they'd want it, and what would the integration be in their systems? We map out a roadmap, and it's, you know, here's the work that they would do, here's the work that we would do. That turns into, you know, depending upon the stage of the business, a, you know, a development agreement. That development agreement would mean that, you know, they pay us a licensing fee for our software, just like with NVIDIA, you're paying for a license for their CUDA. They'll buy chips, and they'll do labs, and they'll do development.

If they ask us to help them refine certain things, then they'll pay us engineering fees to be able to help them do that. Then there's some point in time where they realize, "Well, okay, I have a line of sight to what this means to us commercially." You know, and they will either, who, like with NVIDIA, will just purchase their product and use it, or they will be someone to say, "Well, gosh, if I could be the only one in the world to use it for this use case, would you be willing to license it specifically?" And that's where those conversations go.

You know, these are multiple steps, but what this means is Butterfly shareholders are now tapping into entirely new markets that are well beyond point-of-care ultrasound with opportunities to have very vibrant and profitable recurring revenue streams without having to do the market development that we're doing in point-of-care ultrasound, without having to hire the sales force and supporting a public company in back office costs. It's simply we get license fees, and we're able to sell our chips, and we now have an option to grow revenue in entirely new markets that would take us a lot more capital than we've had to deploy so far in order to build. It is an exponential flywheel. We've been developing. Fortunately for Butterfly, you know, from day one, we've built our architecture to support this. We are cloud-based.

We are app-based, iOS, Android. We integrate with SaaS. We have our hardware. A lot of these components, it turn into the application that our partners are looking for. They're not just licensing our chip, but some of them wanna use our cloud. Some of them want to use our SaaS-based Compass platform for data aggregation. These partnerships are very viable, but it does take time to onboard. There is diligence, there is lab work. But, you know, when we say a new partner comes on, that's a big check because that is a wonderful opportunity for us to increase the TAM of Butterfly and to bring more revenue and market opportunity for our investors.

Great. Appreciate all that color. John, maybe one for you just on guidance here. You know, it seems like there's a lot of tailwinds here between the Garden expansion, the Compass AI contract, you know, moving into home care in the second half of the year. Can you maybe just sort of unpack for us the underlying assumptions? What's in guidance now from a revenue perspective, and what's a potential upside lever? Thanks.

What's in guidance now is everything that we have, you know, a line of sight, of, including, you know, across our core business with probe sales. You know, Joe talked to home. You know, we have some of that in there as well. You know, in the second half of the year, you talked about Compass AI. The things that we have a very good line of sight on are in our guidance. Other things that we might be in the process of negotiating. You know, for example, like if you look at, that could be potential upside down the road. It's early in the year. As you know, we just, you know, printed the first quarter. Ultimately, you know, I'd say our posture's gonna be a little bit more on the conservative side, but we reaffirm guidance.

We're very confident in where we're going for 2026. In addition, if you look at adjusted EBITDA, obviously we had a beat in the quarter, ultimately we are investing in certain areas of the business. With the launch of Home, it does require some investment to get it off the ground, and ultimately it will be a positive. You know, it has a very strong ROI for us, that takes time. We're not in this to just, you know, have a really solid 2026. We're also in this to continue to grow at the rates we're growing at for the foreseeable future. You know, we're talking about years here, not just quarters.

Great. Thanks, guys.

Thank you.

Thank you, Andrew. Our next question is from Ben Haynor from Lake Street Capital Markets. Your line is now open. Please go ahead.

Good morning, guys. Thanks for taking the questions. First off for me, you know, obviously great to hear the FDA enthusiasm on the gestational age AI tool. You know, presumably this derisks kinda the future blind sweep AI like tools from you guys. I would imagine that it also does so for folks that might be looking to develop something similar for Butterfly Garden or Butterfly Embedded. You know, any more color you can kinda share there? Has it piqued more interest? You know, what has that done for you guys?

Well, I think, I think what is important, I think what the FDA is pointing to is, you know, there are a lot of people I imagine right now, I don't have access to the data. I would imagine there are thousands of applications in the FDA for clearances of AI tools. I would imagine that, you know, a very high percentage of those are, you know, probably not doing it in the manner of treating it like a device or treating it like something with consequence. You know, people at times just think software is software. When you're gonna inform a patient and that information is gonna change their clinical pathway, right.

You know, we have taken a longer path with the Gestational AI tool. We've done a lot of clinical work. We've done a lot of work with the University of North Carolina and Jeffrey Stringer. We've done a lot of work making sure. You know, cause remember, this blind sweep, there's no image that anyone's looking at. Blind sweep the pregnant abdomen, and it spits out an age, and so it's gotta be right. You're not doing it based upon, you know, looking at an image.

I think what the FDA saw was that here's a company who took this seriously, understood the consequence, the incredible upside value proposition, and did the work to validate the AI, just like you would do the work to validate any type of device that was going to intervene into the body. I'm proud of our regulatory and quality teams for holding such a high standard. I'm proud of our management team for not being short-minded. You know, a lot of times people get in and they argue with FDA. They try to convince them that, you know, it shouldn't be this way, it shouldn't be that way. You know, sometimes FDA is wrong. They're not perfect, and sometimes they need persuading or educating and whatnot. I'm certainly on that, on that front.

After my 30 years of putting products through FDA, I think the world is better because we have FDA. FDA keeps us safe. I think FDA keeps us on our toes, and there's always someone who's wrong or someone who might overdo it or underdo it. The process, I think, leaves the world in making sure that this technology works. When you get through that gauntlet, then you now have, you have a moat, and you have because you've earned that moat. We have that over every ultrasound company in the world. We are now actively working with partners, ministries of health that have been waiting for this for years.

If, if you've heard of some of the visionary statements from the Gates Foundation, they've always believed that AI and ultrasound is probably the biggest catalyst to improvement of overall care for these developing countries because of the power of these diagnostics, you know, in these remote areas. I think this is a tool that is going to now, excuse me, translate into revenue by there being large deployments of probes and systems in all these different places. You know, we accomplished something a year and a half ago, two years ago, that was extraordinary.

We trained 1,000 midwives in Africa who are managing over 80,000, you know, women who are having childbirth, and they're doing, I think about 80,000 scans a month to make sure that they identify the fetal position of the baby. 20,000 women a year die in childbirth just because they were not able to get the baby out, which is horrible. Like, you can't even imagine that. You know, with the Gates Foundation, we've trained those 1,000 midwives, and they're now improving care every single day. With the architecture that Butterfly has, we can just push this new tool to all 1,000 of their probes and get them now, you know, being able to identify the age earlier.

These are significant flywheels in the acceleration of patient care, and that's being done on the architecture of Butterfly. We're proud. For the FDA to go to their social media part to specifically call out Butterfly, you know, I think it makes us proud. It makes us feel like we're doing something right, and that we're a real company who really cares with terrific technology, who has profound respect regulators, and I think they've returned that respect.

The FDA communicating is definitely a feather in your cap. You know, overall, just a fantastic update here this morning. The one thing that maybe I missed, and I apologize if I did, any updates on kinda additional form factors? I know historically we talked about the iQ station and things like that. Anything else on that front? That's it for me.

Thank you, Ben. We appreciate the questions. We didn't call it out in this particular call, but as an update, early next year, we will have a new probe and we will detail, you know, the capabilities and the branding and the cost and everything. I think probably closer to the end of this year, beginning of next. That is online. That will bring to market the, you know, not only bring our ultrasound on chip technology, but it'll be the first ultrasound on chip that has, you know, harmonics with CMUT, so thrilled with that innovation. We are actively working on our station, and that is also in early to mid, you know, 2027 timeframe.

We didn't chronicle it, but it is very much still in our work. Also, you know, we've talked about wearables for a very long time, and we have a wearable today. If we went and launched that wearable, I don't know what that market would be for it yet. What we are doing is building out applications in home, and then, quite frankly, several of the embedded partners are wearable partners, where they not only want the ultrasound on chip, but they're developing a wearable form factor around what we've created. Then they are developing applications for clinical application of that wearable. I would think that the first wearable that comes to market would be through one of our embedded partners into some extraordinary use cases that they're developing.

You know, we are, you know, we do have a lot of resource focus on new technology development and software and AI and hardware. But we are able to accelerate our market opportunity as we partner with other companies with visions and novel ideas for them to be able to create whole new markets. Those are probably the devices that you'll be seeing from us over the next several years.

Great. Can't wait to see what's next. Thanks a lot, guys.

All right, my friend. Thank you.

Bye-bye.

Thank you, Ben. We currently have no further questions, so I will hand back to Joe for closing remarks.

Everyone, thank you so much for the interest. You know, I know that the macro environment has a bunch of ups and downs, but I think we're gonna be swimming upstream of those. We have a lot of tailwinds. You know, we had tremendous growth last year, tremendous, you know, probe growth. We have tremendous new product launches. We are coiling up opportunities for Garden and Embedded. We are coiling up opportunities for more one-to-one medical schools and enterprise. This is a time when we are, you know, our foot's on the accelerator, we're stretching our legs, and we're making things happen. We appreciate your support and the unbelievable energy of all of the employees of Butterfly who are actively changing the world. Thank you all.

Thank you. This concludes today's Butterfly Network Inc Q1 2026 Earnings Call. Thank you for joining. You may now disconnect your lines.

Hello, everyone, thank you for joining the Butterfly Network, Inc. Q4 and FY 2025 earnings call. My name is Gabrielle, I will be coordinating your call today. During the presentation, you can register a question by pressing star followed by 1 on your telephone keypad. If you change your mind, please press star followed by 2 on your telephone keypad. I will now hand over to your host, John Doherty. Please go ahead.

Good morning, thanks to all of you for joining our call today. Earlier, Butterfly released financial results for the fourth quarter and full year ending December 31, 2025. We also provided a business update. The release, which includes a reconciliation of management's use of non-GAAP financial measures compared to the most applicable GAAP measures, are currently available on the Investors section of the company's website at ir.butterflynetwork.com. I, John Doherty, Chief Financial Officer of Butterfly, along with Joseph M. DeVivo, Butterfly's Chairman and Chief Executive Officer, will host the call this morning. During the call, we will be making certain forward-looking statements. These statements may include, among other things, expectations with respect to financial results, future performance, development and commercialization of products and services, potential regulatory approvals, revenue attributable to embedded collaborations through revenue share, chip purchases or otherwise, and the size and potential growth of current or future markets for our products and services. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our filings made with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligation to update such statements. As a reminder, this call is being webcast live and recorded. To access the webcast, please visit the Events section of our investor website. A replay of the event will also be available on this page following the call. I will now turn the call over to Joe.

Thanks, John. Good morning, everyone, and thank you for joining our fourth quarter and full year 2025 conference call. I am pleased to announce that our fourth quarter revenues came in at $31.5 million, growing 41% year-over-year. It is also the first quarter in our history where we realized positive operating cash flow, driven by upfront payments from our Midjourney deal. We are now nearly two years into our strategic growth plan that we introduced in early 2024. The message was clear: execute with focus and financial discipline, strengthen our core franchise, and unlock the full value of our semiconductor ultrasound platform beyond handheld devices. We are doing just that, and we now have material contribution outside of our core POCUS business. Earlier this month, Jim Cramer was asked a question about Butterfly Network on Mad Money, and he said, I quote, "It is a very competitive market, and I do not want to be in that part of the medical device group. Too hard for this guy, just too hard." You know, I am a big fan of Jim Cramer, and like you, watch CNBC every day, and he is right about one thing: traditional medical devices are a tough sector, but Butterfly is not a traditional medical device company. We were never just a handheld company shaking at the knees of big ultrasound. We are David, faithful and committed to our cause, not backing down regardless of how large our opponent is. We are the disruptor. We are playing our own game with our own rules and our own playbook. We are digital eating analog's lunch and plan to revolutionize imaging with digital ultrasound everywhere and images taken. Goliath just does not know it yet. We are changing ultrasound imaging with our differentiated chip platform while deploying secure cloud software, AI tools, and mobile applications, and are the only healthcare company in the world over the last seven years to receive an Apple Design Award. We are not a medical device company alone. We are a transformative semiconductor-based ultrasound company. As you are all aware, the strategy we introduced has three core tenets: accelerate our core POCUS business with an enterprise-ready, cloud-connected imaging solution, execute strategic initiatives to reach new care settings and enable entirely new applications, namely home care and Ultrasound-on-Chip co-development. Lastly, deliver an R&D roadmap that sharpens our technology edge with next-generation chips and new form factors getting more and more powerful and capable. Let me walk you through the progress in each of these. In core POCUS, revenue grew 15% year-over-year on top of a 35% growth in the fourth quarter of last year, which, as you recall, was a record product launch year. We closed a second large system-wide enterprise deal in the fourth quarter of 2025 and continue to deepen medical school and enterprise relationships. I will let John cover the financials in more detail, but we feel much better about macro trends and the deal cycle than earlier in the year and expect to carry that momentum into 2026. The fourth quarter Compass AI launch is a big tailwind for our enterprise strategy. Enhancing our enterprise solution helps refresh existing accounts, continue attracting new customers and drove more than 50% growth in our enterprise pipeline since launch. At the same time, we have been building what we believe is one of the most secure cloud infrastructures in healthcare. In the U.S., we most recently achieved GovRAMP and TXRAMP, and FedRAMP is anticipated in the coming months, meaning we will soon be even more qualified for cloud deployments in now the world's largest government market. Internationally, we see meaningful opportunities in 2026 as we open markets in South America and continue expanding across Middle East and Asia, alongside a renewed momentum in global health. We have surpassed 1,000 NGO partners worldwide, and many expect to increase activity in 2026. We also continue to make progress in our Butterfly Garden partners, and as you know, HeartFocus became the first FDA-cleared app in 2025, and we expected additional partners to reach that clinical milestone in 2026. We announced plans to release our proprietary beam steering API in the first half of this year. The API will open 3D imaging capabilities that have been reserved for Butterfly products only. Because our beam steering is fully digital on a semiconductor chip and not mechanically driven like other legacy systems, we can uniquely extend those capabilities to partners. The goal is to advance what they can build, expand the AI ecosystem, and help accelerate ease of use. We are excited about the new opportunities this welcomes. Moving to the strategic growth engines. We have built a home business determined to accelerate the use of POCUS devices where the patient is, expanding the reach and empowering nurses and other clinicians to perform scans using AI tools. I believe we will reach a commercial agreement in 2026, allowing home care to enter its commercial phase. This is a powerful new channel that reduces hospital readmissions, lowers costs, and expands Butterfly's reach beyond the hospital. Home care is a reality, we think it can be a real growth driver, starting to add revenue in late 2026 and into 2027. We also ventured out to develop a new business to make our core Ultrasound-on-Chip available to companies with large new market opportunities that are not competitive with Butterfly's focus business. That was previously known as Octave. Well, to start the new year, we have officially sunset the Octave name and have centralized our semiconductor platform strategy under Butterfly Embedded, reminiscent of the Intel Inside model. What began as an adjacent effort is now emerging as a foundational business, enabling other category-defining innovators to build entirely new application on Butterfly's Ultrasound-on-Chip technology. The big news for the fourth quarter, though, was signing Midjourney deal in November, and as you can see today, it contributed $6.8 million of revenue in the quarter and was a key driver of our 41% year-over-year growth. Midjourney is an independent research lab pushing the boundaries of generative AI and human imagination. Their scientists have envisioned a breakthrough new application for ultrasound that we believe the world will be learning about very soon. This partnership combines Butterfly's core Ultrasound-on-Chip technology and imaging software with Midjourney's generative AI compute power to do something very special with ultrasound. This deal is more than revenue, it is validation. It is a foundational step towards Butterfly's reinvention into a platform company. The initial partnership and revenue contribution is pre-commercial. Based on the plan that Midjourney has shared with us, once commercial, we believe there is meaningful additional revenue opportunity for Butterfly in the form of chip sales and revenue share on top of the licensing fees that will continue through the deal. We expect this to happen in the outer years of our 5-year plan, and if it occurs, could represent meaningful progress towards our goal of reaching $500 million in annual revenue by 2030. Beyond Midjourney, we signed an additional Butterfly Embedded research share partner this quarter and expect another one shortly, while managing an active pipeline of some of the largest technology and healthcare companies in the world. Before I look ahead to our R&D roadmap initiatives, I will turn it over to John to discuss the financials. John?

Thanks, Joe. I am very excited to have joined Joe and the talented team here at Butterfly, which includes Megan Carlson. Megan, who you all know, did a great job in the interim CFO role and has been an awesome partner to work with, along with the rest of the leadership team. With about three months behind me, I want to open with a few comments and my thoughts on Butterfly overall. I joined Butterfly because I was excited by the incredible potential this company has going forward to provide a valuable and meaningful experience to our customers, as well as to create value for our shareholders. I was also impressed by the strength of the leadership team and the passion and commitment demonstrated by employees across the company. This is a company I am proud to be a part of. Butterfly certainly navigated a few challenges in its early years as a public company. However, the company has made the necessary difficult adjustments, including improving its operating efficiency, choosing the markets it can win in, selecting the best ways to leverage its IP and technology advantage, and allocating its resources towards higher ROI opportunities and markets. No doubt, based on these actions, Butterfly is a stronger, more agile company today. With continued steady execution, the company has the potential for significant core growth in an incredibly meaningful domain through its focused and related conscious AI software and Butterfly Garden business, and we are well positioned to gain outsized share in the markets that we compete in. We also have a significant opportunity to leverage our core platform of Ultrasound-on-Chip into other nascent and disruptive markets consistent with our strategy through Butterfly Embedded, as the Midjourney partnership demonstrates. With that, let us move on to a few highlights for the fourth quarter, including a record level of revenue for the quarter and exceeding the high end of our total revenue and adjusted EBITDA guidance ranges, a record level of quarterly probe sales, significant improvement in adjusted EBITDA margin, driven by our revenue performance and continued financial discipline, the lowest annual cash use in the company's history, and we generated positive free cash flow in the quarter, and the execution of the Midjourney contract, which helps to solidify and amplify all of our efforts to drive a new wave of ultrasound-enabled platforms and use cases through Butterfly Embedded. Let me move on to our results. We had a strong fourth quarter of 2025, with revenue of $31.5 million, the highest quarterly result in the company's history. This represents a 41% increase year-over-year for the quarter. The increase is driven by increased revenue from Butterfly Embedded, as well as a 27% increase in year-over-year volume in our core focused business, with continued penetration of the iQ3 in all markets. The 41% year-over-year growth is significantly higher than the at least 17% year-over-year growth that we put out in January. We did better in the core business and realized more revenue from Butterfly Embedded, given the work we had already performed relative to the Midjourney contract. This is the primary reason we used the at least language at the time, as we were still finalizing the accounting treatment. Our results and the guidance I will provide later in the call for first quarter and full year 2026 all include updated financial expectations from this contract. Breaking things down between the U.S. and international channels, during the quarter, U.S. revenue was $26.8 million, which was 55% higher year-over-year, driven by revenue from Embedded, as well as strong demand in the core business, with unit sales up 44%. Total international revenue decreased by 6% year-over-year to $4.7 million in the fourth quarter. While sales of the iQ3 in the quarter were up 42% year-over-year, sales of the iQ+ were down 79%. Breaking our revenue down between product and software and other services, product revenue was $18.1 million, an increase of 23% versus the fourth quarter of 2024. This increase was driven primarily through growth in volume across all channels, with U.S. health systems, e-com, and vet leading the way, as well as higher average selling prices in international markets with the higher mix of iQ3 sales. Software and other services revenue was $13.4 million in the fourth quarter, up 76% year-over-year. Software and other services mix was 43% of revenue, increasing from 34% in Q4 2024. This increase can be attributed to the significant step-up in revenue contribution from Butterfly Embedded in the quarter, related primarily to the Midjourney partnership. I will talk more about this as well when I come to guidance for the first quarter and full year 2026. When looking at the full year 2025 versus 2024, total revenue increased 19% to $97.6 million. This was driven by two areas. First, growth in our core focused business, with both increased volume and a higher average selling price, driven by an increased mix in the sales of the iQ3 and strong performance by U.S. sales, our vet channel, and international distributor channels. Second, growth in our emerging Butterfly Embedded business, primarily from the execution of the Midjourney contract in November of last year. Moving on to gross profit. Gross profit was $21.2 million in Q4 2025, a 55% increase as compared to the prior year adjusted gross profit of $13.7 million. Gross profit margin percentage increased to 67% from 61% in the prior year period. Gross margin percentage was positively impacted by the higher-margin Butterfly Embedded revenue and lower software amortization. Moving to EBITDA and cash. For the fourth quarter of 2025, adjusted EBITDA loss was $3.2 million, compared with a loss of $9.1 million for the same period in 2024, an improvement of 65%. For the full year 2025, adjusted EBITDA loss was $26.5 million, compared to $38.9 million for 2024, an improvement of 32%. The improvement in adjusted EBITDA loss for both the fourth quarter and full year was driven by contribution from higher margin revenue and continued financial discipline reflected in our lower year-over-year payroll costs for the quarter and full year. This improvement in adjusted EBITDA and continued financial discipline has led to a cash and cash equivalent balance, including restricted cash at year-end of $154.5 million, and the use of cash in 2025 of $19.4 million, excluding the funds from our offering last year. This compares to a use of cash of $45.9 million in 2024, an improvement of $26.4 million. We also had positive cash flow of $6.3 million in the fourth quarter. These results demonstrate that we are very well positioned as we move forward to continue to invest in the business areas where we see significant opportunities for additional growth and disruption, including expanding our core POCUS business and penetration of Compass AI as a core operating system for health systems. Continuing to enable third parties to build tailored ultrasound AI solutions in Butterfly Garden to provide deeper and expanded access to our platform. Expanding our home care business following the execution of our anticipated first commercial agreement, which we believe could be finalized in the first half of 2026, as Joe mentioned earlier. Enabling a new wave of Ultrasound-on-Chip-enabled technologies through Butterfly Embedded, and continued AI and semiconductor innovation with the development of our 4th-generation chip. Before turning to guidance, I want to update you on the general macroeconomic environment relative to Butterfly. While there were some concerns in 2025 relative to the government shutdown and impact on the FDA's processing of fee-based submissions, regulatory processing delays, and delays in customer purchasing decisions, we have managed through this, and it is very much behind us. Our fourth quarter results are indicative of that, and we were able to close some of the larger deals in the pipeline and still have a number that are active. I would now like to turn to our outlook for the first quarter of 2026 and for the calendar year ending December 31, 2026. In the first quarter, we expect revenue in the range of $24 million–$28 million, as we ended the fourth quarter somewhat higher than expected, and the first quarter is typically a slower quarter for the company due to seasonality. As is typical for Q1, adjusted EBITDA is impacted from expenses related to payroll tax and 401(k) reset, as well as our national sales meeting and POCUS Innovators Forum, which took place in January. As a result, we expect slightly higher expenses and higher adjusted EBITDA loss in the first quarter relative to the remainder of the year in the range of $8 million–$10 million. For the full year 2026, we expect revenues to be between $117 million and $121 million, an increase of approximately 20%–24%. We expect our adjusted EBITDA loss to be between $21 million and $25 million. Our guidance for adjusted EBITDA includes investment in key areas to support continued innovation, as well as our emerging embedded business, as well as the impact from tariffs initiated in 2025. In summary, we had a great quarter, a record quarter. We closed the year out strong, we exceeded expectations for revenue and adjusted EBITDA, and we are very well positioned going forward. As our 2026 full year guidance indicates, we look forward to continued growth this year and beyond, and our overall outlook on the business is brighter with this past quarter reinforcing our view. In 2025, we believe the company enhanced its position in the core POCUS markets and can continue to gain share in 2026 through deeper penetration of existing customers, new customers, and applications. We also amplify our Ultrasound-on-Chip platform and the potential of Butterfly Embedded with the licensing partnership with Midjourney. We did all of this while continuing our intense focus on driving operating efficiency across the business and ROI. As I said up front, I am excited to have joined Butterfly late last year, and I am excited about what is ahead for the company in 2026 and beyond. Now, let me hand it back to Joe for some closing comments.

Thanks, John. It is an exciting time for Butterfly. We are in a strong position and are delivering on all fronts. The future is even brighter. Before closing, I will touch briefly on R&D. We recently spent two days with 60 leading POCUS thought leaders at our annual POCUS Innovators Forum, and the alignment was unmistakable. The goals, needs, and future state vision shared was directly in line with where we are taking our portfolio. That level of synergy only strengthened our conviction that we have a path to enable every doctor and nurse with powerful, affordable, compact imaging and can meaningfully unlock enterprise adoption. As I mentioned on the last call, our fifth generation P5.1 chip was moved to production by year-end. We are excited in achieving harmonics and delivering a new level of imaging for handheld ultrasound. This will open additional subspecialties and support our enterprise selling efforts in 2027 and beyond. Next up on our chip roadmap is Apollo. This new chip architecture is now receiving the full attention of our engineers and will deliver 20 times the current data rate and compute performance, ushering in a new era of digital imaging and AI. We are already working with several Butterfly Embedded partners based on the capabilities of this platform. I would like to close by sharing exactly why I am so excited about Butterfly's current chapter. We are pioneering semiconductor-based digital ultrasound everywhere it is needed. In the traditional ultrasound market, that means continuing to lead in point-of-care solutions that truly meet the demands in and out of the hospital, empowering doctors, nurses, and caregivers, expanding new subspecialties, strengthening our enterprise roadmap, moving imaging to the bedside and beyond it. It is also bigger than that. Ultrasound is being researched and deployed in brain therapy, continuous monitoring, robotics, organ preservation, and the list goes on. If you do a simple search of ultrasound in the magazine Nature, just this month alone shows applications in neuromodulation, ablation, antiviral therapy, and soft robotics. The real inflection point comes when ultrasound in these use cases move to silicon, when it becomes programmable, power efficient, AI native, scalable. That is the common thread. Whether it is a Butterfly handheld in a clinician's pocket, a new form factor on our roadmap driving enterprise or home adoption, or a partner building something novel with our technology that we can never do ourselves, it is the same core technology, the same architectural advantage. We are not just building devices, we are opening markets. We are enabling a new age of digital ultrasound imaging and sensing, all in one strategy. This is Butterfly. We are not just a medical device company. We are a true disruptor building the ultrasonic backbone of the AI era and one of the most exciting technology growth stories in healthcare and technology today. With that, operator, please open it up for questions.

Thank you, Joe. To ask a question, please press star followed by 1 on your telephone keypad now. If you change your mind, please press star followed by 2. When preparing to ask your question, please ensure your device is unmuted locally. Our first question is from Joshua Thomas Jennings from TD Cowen. Your line is now open. Please go ahead.

Hi, good morning. Thank you. Impressive to see all the progress in so many different channels. Gives us a lot to ask about, challenging to choose one of those lanes, wanted to start with Butterfly Embedded and just, absolutely. Just wanted to better understand, and you may not be able to share, but any details around potential timing of the technology offering that Midjourney is going to put forward, implementing Butterfly's semiconductor and ultrasound chip technology? Any help just thinking about the cadence of revenue contributions from this partnership over the course of 2026 and what is embedded in guidance?

Thanks, Josh. Well, I will let John answer the second part of that in a moment. Let me just get to the first. I think we are probably going to see something, you know, in the relative near term from Midjourney. You know, one of the things about a Butterfly Embedded program is we are enablers for our partners. This is not our business, this is their business, and we do everything we can to amplify their business. I do not want to get out ahead of them, and all I want to do is do everything that we possibly can as a partner to support them. That said, I think, you know, they probably want to get this out sooner rather than later. The moment they do, you know, we will do the best to show you how it, you know, translates into Butterfly. John, do you want to take the second part of that?

Yeah, sure. Thanks, Joe. Appreciate it. How you doing, Josh?

Good.

So—

Thanks a lot.

when you look at Embedded, you know, obviously, yeah, as Joe touched on during the opening remarks, Midjourney kind of lit it on fire, if you will, with the contract we signed at the back end of 2025. We are very excited about that contract. There is also, you know, a number of other partners that we are working with in Embedded. While right now, Embedded and our revenue is, you know, there is a big contribution from Midjourney, we do expect, you know, other contributions from other partners that we have in there, and, you know, we are really excited about what that part of our business can be, as we discussed at the back end of 2025. You know, relative to Midjourney, it is a $74 million contract, as we mentioned. There are different components of it. You know, there is the upfront payment, there are annual license fees, and then there is milestone work that we do that ultimately, you know, allows us to, you know, do the, you know, take the revenue, ultimately, you know, quarter by quarter, if you, if you will, year by year. You know, we expect to get a good amount of contribution throughout 2026 into 2027 from the contract. In addition, when they commercialize, ultimately, you know, as Joe mentioned upfront as well, there is an opportunity for chip sales as well as for a revenue share as part of their business. Ultimately, really excited about the overall contribution from Midjourney, but Embedded is not just Midjourney.

No, I appreciate that answer, and kind of leads into my next follow-up is, I mean, our understanding is that the team was focused on the Midjourney partnership and development work and then locking that in in 2025, but there were some other potential partnerships on the periphery that sounds like you guys are engaged and moving forward. Any help thinking about the Butterfly Embedded pipeline that you just referenced?

Yeah. I mean, we are talking to a lot of people. As I mentioned, some, you know, very large organizations and also a lot of startup organizations. Kind of the way it works is, you know, we saw a, you saw a contract in the 8-K with Midjourney, in November of 2025. They had been an embedded partner for over a year prior. So the way it kind of works is, you know, people will buy a license to our software, and then they will start buying chips, and they will do some research. They will do research, you know, as far as how does, you know, does a chip meet their performance that they need? How does it integrate with their systems? Then, and they do a bunch of work. You know, whenever they are done and ready, you know, if everything worked out well, then it will turn into a commercial agreement. They will come back and say: "Okay, well, we want to now do, you know, X, Y, and Z." That is kind of how Midjourney happened. There is really no formula. It is just, you know, we have, I think, now, eight or nine embedded partners today, and the pipeline is pretty large. It is also, you know, we are not selling off-the-shelf product. You know, we have to take our product, and we have to do labs and show them how it can fit with their tech and whatnot. It is a bit of a sales process, but, you know, do we have another Midjourney in there? I hope. You know, there are some very big opportunities people are going after, massive opportunities, actually. You know, we are going to continue to add people into the research phase of our relationships and do everything possible to meet their needs and get them, you know, committed to a commercial phase, like Midjourney did.

Excellent. Maybe one question on the home care franchise, and it sounds like you have made progress in this first commercial partnership. I mean, what steps are left before that commercial effort kicks in? Maybe just remind us of the home POCUS market opportunity or the revenue opportunity for Butterfly in this channel. Thank you, guys, for taking all the questions.

Hey, thank you, Josh. Appreciate them. Yeah, I think, you know, we are pretty confident that this is going to, you know, get to a commercial conclusion. You know, as John said, in his notes, we think it will probably happen before middle of the year, which will give us the second half of the year to start getting it ramped up. It would probably be nominal revenue in 2026, but start contributing in 2027. Once we get it started, and we have a line of sight, and we are able to give a better shape of what the impact is, we will tell you as far as, you know, and incorporate it into our guidance. You know, in aggregate, I think I have mentioned in the past, you know, if just this one use case we are working on, if it became a national use case, it could be a $40 million–$50 million revenue opportunity if everything went, you know, the way that we saw it. That is. You know, when we think about the amount of chronic care patients are in nursing homes and also the amount of patients that are in the home, who are being cared for by nurses, you know, as they get sicker, they need to be, you know, moved. They need to have an image. You know, they have to go to the hospital, whether it is by ambulance or by some other transport, be brought up into radiology and then have, for example, a cardiac echo or something else. You know, empowering caregivers to be able to take images where they are is efficient, is low cost, and has high impact on being able to quickly give a diagnosis for a patient so their meds can be modified to make them healthier and keep them into the home, or keep them wherever they are. That is literally every facet of healthcare is about being where the patients are, being where people are, and helping them get healthier faster in the lowest cost environments. You know, our home care business is basically an extension of our POCUS business. It is not a third business; it is an amplifier of POCUS. You know, ultimately everyone will figure it out, and they will use our stuff to do all of this using the AI apps, etc. Home is kind of a catalyst for us to, you know, take a lot of the workflow, the logistics, and the ramp-up and the learning curve out. I have mentioned before that we think the home business can be bigger than POCUS, and the opportunities are certainly there. We have, you know, we have to prove it, and we have to get some more... Our pilot was excellent. We need to get, you know, the first few states up. We need to prove what we are doing there. We need to prove we can go to a larger geography. It is a process, but it is a big opportunity, and it will teach, you know, core healthcare providers and payers that point-of-care ultrasound with Butterfly is a significant way to reduce costs at the exact same time of improving quality and care for patients.

Thank you, Josh. Our next question is from Chase Richard Knickerbocker from Craig-Hallum. Your line is now open. Please go ahead.

Good morning, guys. This is Jake on for Chase. I was wondering if you could, maybe, John, if you could give us any more color on the macro environment, if you guys are seeing any of the same trends that affected 2025 and how they are abating now in 2026?

Sure, and I appreciate the question. As I touched on, you know, with the opening comments, I am not going to say everything is behind us, but certainly, you know, we feel, you know, a lot more confident going forward. Irrespective of the Supreme Court's action relative to tariffs, you know, it is still a very mild, say mildly, and an unpredictable area, given what happened post that. You know, we do still expect to have a bit of some downward pressure. Not a lot, but some downward pressure from tariffs. We did sign a number of contracts late in the year, so we see that things have been opening up a bit there. We still have a number of, you know, good-sized deals in the pipeline. I would say, you know, the timing did move out kind of the back half of last year as the company had touched on when they did third quarter results, but we are seeing some improvement there. We are starting to see some things move. Ultimately, as I mentioned, you know, the company, we are managing through it, and we do not expect it to have except for the, you know, the tariff component, we do not expect it to have a lot of impact on the company.

Great. I appreciate that color. Apologies if I missed this, but is there any more color on the opportunity with medical schools going into the year as well for the one-to-one partnerships?

Yeah. Medical schools, I think, should be a pretty, a pretty strong contributor to us this year. You know, the, you know, second quarter of the year is the big medical school quarter when we, when we put them all in. We have a lot of conversations for one-to-one buys, and you know, we did get a bit of a pause last year when the decision to cap student loan debt occurred, and so it caused people to pause. You know, what is so exciting about what we are doing is there is such a strong commitment for new medical students to learn ultrasound. They are actually now starting to choose where they go and the types of programs they get into based upon the commitment of building that competency. You know, kids that are graduating today, and are going into their residency, completely distinguish themselves when they have this capability. Even, you know, even their, you know, their attendings, who are working with them, you know, are kind of, surprised when they see what can be done by a resident with ultrasound skills. There is not a lot of daylight out there. This is not a new thing. Students want Butterfly. They are trained on Butterfly. They want that experience, and then when we build the brand equity with these students, they go into their residency and then into practice with that loyalty, with that understanding, and we are looking to grow with them, especially, you know, with our whole, you know, chip platform improving and getting more and more powerful, and then more apps coming in over the years. You know, we are going to grow with them through their career. We start off with medical schools. Medical schools will be a very positive contributor in 2026.

Appreciate the answers, guys. Thank you.

Thanks, Jake.

Thank you. Our next question is from Andrew Frederick Brackmann, from William Blair. Your line is now open. Please go ahead.

Hey, guys. Good morning, thanks for taking the questions. I will echo Josh's comments. Certainly a lot of progress here and a lot to dig into. Joe, maybe with that in mind, I would like to start a little bit higher level. I mean, it is sort of hard to miss the underlying transformation going on here, towards Butterfly Embedded. Can you maybe just sort of talk to us about why now for this transition from med devices towards embedded and the semiconductors type of business? Then just as you sort of think about organizational focus, perhaps, are there any sort of changes in terms of your view on focus versus the opportunity with Embedded? Thanks.

That is a great question, Andrew, and I actually, I probably should have emailed that to you and planted that in, because it is, that is a very appropriate question. You know, we are not trying to pivot away from focus. You know, we, you know, we want to have every doctor and every nurse in the world, have a device that allows them to help diagnose their patients sooner, easier, low cost, where they are at. We will never, you know, move away from that vision. You know, in accomplishing that vision, Andrew, we solved the problem. We solved a major problem in technology where we can digitize, we can digitally control the ultrasound image. We can control it in a way that is much more than what medical ultrasound uses with, you know, multiple planes and depths. Because we control 9,000 sensors in a rectangle, which allow us to send out information, send out sound a certain way, and listen to sound a certain way. You know, what we solve for ourself for point-of-care ultrasound is a major solution for many other people out in the marketplace. You know, there is this whole concept that AI and the human body are going to merge together. You can Google it. There is a whole sci-fi fantasy out there. You know, there. If you even think of brain-computer interface, you know, Neuralink today is putting wires into the brain. There is this thing in DCI called the butcher factor, which is, you know, how many neurons do I have to kill before I get to the neuron I want to talk to? Well, one of the beautiful things about ultrasound is, and about Butterfly, is we do not have a stagnant beam that sits in a fixed position. You know, normally, ultrasound is like a flashlight. You know, you have to move the beam in order to capture the image. We can actually, in a fixed location, move our beam and scan. If you implant something in the brain, you are going to be able to communicate and see and listen to 25% of the entire brain or the entire lobe. It is being seen today that ultrasound is potentially a portal between AI and the human body. Just read Nature and you will see all these articles about brain-computer interfaces, and you will hear about ultrasound, you will hear about neuromodulation, you will hear about all different types of, you know, even if it is therapeutic, people are going to be looking at the brain signals through vasculature and how vasculature flows through the brain. It ultimately, you know, you can potentially heat it and put energy. This is kind of happening. It is not like we just did a prospect, a randomized study, and we are now pushing the market. The market is calling us. They see our 600 patents, they see the excellent technology that we have, and quite frankly, we have been approached prior to me getting here by companies asking to partner with them, but they were turned away because the company was trying to focus on point-of-care ultrasound. What we have said to ourselves is, "No, we have solved the foundational problem." you know, I would hate to compare ourselves to NVIDIA because there is no way there is a scale or anywhere to draw a line. You know, from 93 to 2005, they were a video game company, and they focused on their core markets of building technologies to be better gamers, that had to be complex. You know, and then with CUDA in 2006, it opened up their platform for developers who could use these incredible chips for other applications. You know, or you look at Amazon, you know, they did not set out to become the leading cloud compute company in the world. They realized that they needed cloud compute. There was not a large enough vendor to take their volume. They built it themselves. When they were done, they had excess capacity, and they said, "Let us go sell that capacity." Now it is the highest profit-generating part of their business. Sometimes in business, you solve problems for your customers that benefit others, and we are just simply now allowing ourselves to work with those partners. The beautiful part about it is that the roadmap that we have set ourselves, so, you know, our Poseidon platform, our P5.1 platform, our Apollo platform, we are now not going off and developing new things for other people and losing our focus on Point-of-Care Ultrasound. What we are actually doing is amplifying our current roadmap, and we are exposing our roadmap to those customers and those and to allow them to meet their needs. It actually is going to make our ability to serve point-of-care ultrasound better, and the roadmap that we have for point-of-care ultrasound and what is going to happen, you know, with our next launch of our platform, with Harmonics and P5.1, and what we are going to do with, you know, some new things that we will unveil in 2007, there is so much synergy here, Andrew. It all ties together. We are not putting something on the shelf and then focusing someplace else. We are pulling our core tech, we are partnering with people who have real interest of building businesses and have technical challenges that we can solve. Instead of having an analog ultrasound device that, you know, yes, you have digital behind the lens, but then once you push the signal through the lens, that lens is cut to do one thing. Our lens can be anything, and developers love the fact that they can see the signal and then change the software, see the signal, change the software. That, you know, kind of infinite iteration cycle is how, you know, we will fit our ultrasound into many different types of devices throughout the world.

Okay. That is terrific color. Thank you for all that, Joe. Maybe if I could just sort of switching lanes here. You referenced the Compass AI, and sort of the launch there. Can you maybe just expand on sort of what that does in practical terms for your moat within that focused business? What does it give you that competitors do not have today? As you sort of think about, you know, defending against some of these potential, you know, AI disruptors that are out there, how does this sort of expand the moat there? Thank you.

Thank you so much, Andrew Brackmann. We were, you know, the prior team before I got here, you know, Todd Fruchterman and the team were very visionary on making sure that if Point-of-Care Ultrasound is going to be adopted enterprise-wide, that we need to manage the data. The systems, you know, the EMRs, the DICOMs, all the current hospital systems were not geared and built to operationalize Point-of-Care Ultrasound. Butterfly became the first ultrasound company that invested in an enterprise SaaS-based software that not only allowed it to collect its own data, push it into the record, push the image into DICOM, and set that record up ready to be submitted for reimbursement with the revenue cycle management software. We have built the most powerful, you know, SaaS-based system out there in order to do this. Now hospitals, when they put our software in place, they now recognize scans that were not getting reimbursed, and they increase their revenue and profitability. It is, it is just good, and good. Now, on the other side, doctors hate new things. They do not like to have to go through new steps. They just want to do everything in their EMR. They do not want to have one software for this, one software for that. Getting to an ease-of-use paradigm is essential, because the doctors are already asked, and nurses, to do so much in their everyday lives. To now go into another platform to go through a whole other set of workflow is just something that they dread, regardless of how good it is for, you know, the patient or the economics, it is just more work. Getting our system to be easier, faster, simpler, more integrated into the, their daily workflow and to use the power of AI to where so we take their dictation. Every doctor dictates. If we can take their dictation and then pull apart the data in that dictation and populate the forms for them, you know, those two or three or four minutes that they save is massive to them as they and that multiplies with each patient that they see. We are very committed to making our workflow now. We have solved the major problem of connecting them and aggregating data. Now we are going to be incessant and passionate about making it easier and easier and easier and easier for them to implement, for them to use on a daily basis, for it to be intuitive, and to let the hospitals continue to have the type of ROI they need of capturing all these images. We are never going to stop making it, and we are going to use every new tool available to us in AI to make it easier for our customers.

Great. Thanks, guys. Appreciate the questions.

Appreciate it.

Thank you, Andrew. Our next question is from Benjamin Charles Haynor from Lake Street Capital Markets. Your line is now open. Please go ahead.

Good morning, folks. Thanks for taking the questions.

Hey, Ben.

... for me on the, yeah, how are you? Excellent. Just on your own internal development, pipeline, new P5.1, you know, when should folks expect you to go to the FDA with that? Anything new on kind of the new form factors, whether that is, you know, iQ Station or, you know, in some of the wearable sort of form factors that you showed at the investor day two years back?

Thank you for the question. You know, we are hoping in the beginning of 2027 to have the P5.1 ship into a next program. That is kind of our timing. We think that we just sent it into production. Normally, it would take us some time, you know, late this summer to get them back, and then we start, you know, putting it into the hardware, validating, testing, and then hopefully get our clearance, and then we will be out, you know, sometime early of 2027. That is kind of our schedule. At the same time, you know, we have a vision to bring one-to-one in hospitals and how, you know, we can make a cart-based experience with Butterfly better. iQ Station is actively on our roadmap, and it is probably a later 2027 timeframe for that. We are actively working on that program, and we think that will really codify the one-to-one model on the enterprise side. You know, we are working on making software easier, we are working to make our devices more powerful, we are working to make the workflow in the hospital easier. It is just a fate of it is just inevitable what will happen, and we are on the right path there. You know, on the wearable side, you know, if we wanted to launch a wearable tomorrow, we could, or theoretically, we could, we can put that... Wearables is not an R&D thing, it is more of a what is the use case and what is the market and what is the business? Our philosophy right now is the success of home care will determine, you know, what our wearable use case is. The more that we push ultrasound, alt site, and we push it into nursing homes, we push it into the home, and then the more we will be, "Okay, now this is what it is being used for. This really makes sense. This is sticking, and now let us automate it, and let us make it easier, and let us put a wearable out there." You know, we have there is one of our partners, Forest Neurotech, took our technology and created a wearable. Go on their website, you will actually see it. They put it right there. It is the technology around creating a wearable is not the challenge, it is, hey, what is the business use case? When does it make sense to invest the next several million dollars in hardware to put that out there? Our home care business, in my view, will determine the success and the timing of what is the right use case for wearables.

Got it. That is very helpful. Any more you can share on that POCUS Innovators Forum that you held? That sounds like, quite the interesting event.

You know, you probably need to come next year. I probably have to invite our analysts. You know, we—

No problem.

private the first year. The second year, we brought our whole management team and commercial team in to listen, which was a great education session. I think, you know, what is fascinating about that forum is it is not all one specialty. You have a cardiologist sitting next to an anesthesiologist, sitting next to an ER doctor, sitting next to a primary care doctor, sitting next to an intensivist, sitting next to a nurse, and sitting next to an administrator. They all have a tremendous passion for the power of being able to do a diagnosis immediately at the point of care. We all heard them present their experiences, but we also gave them a forum to tell us what they need. That is where actually Compass AI came from for the, from the last year's forum, was when they said: "It just takes too long to document each one of these records." We went now from four to five minutes down to 30 seconds. You know, we listened to them, and that is why this forum is so important. I think while we had 60 people, we had about 40 people the first year, 60 people the next year, but we will probably open it up to, you know, 100 or more, and even maybe allow you guys to come, too. We learned a lot, and the biggest thing that we learned is that we are on the right track. If we keep listening to our customers, and being honest with ourselves on what we need to do to improve, we will win. It was a great session, Ben.

Sounds fantastic. Lastly, for me, just with Midjourney, you know, you phrase it as a revenue share potential rather than a royalty. Should folks read into that in any way? I mean, that strikes me more as a service offering rather than a device offering.

No, I think you just look into this like a partnership. We are all in with them, and we are doing everything we can to make them successful, and we will do everything we can to make them successful. We do not look at them as someone we are going to sell chips to. We look at them as someone that we are going to invest in, and we are going to do everything to amplify their use case. If all of a sudden we need to do something that was not planned, we are just going to do it because, you know, we both believe in what they are doing, and we are going to be the best partner possible.

Great. Thanks for taking the questions, guys.

Awesome, Ben. Thank you.

Thank you, Ben. We currently have no further questions, so I will hand back to Joe for closing remarks.

Well, thank you all for being with us this morning. I know that this time of the season is busy for all our investors and analysts. I hope you can see the excitement. You know, I think the most important thing, you know, for me is, you know, we put a plan together, and we are executing to our plan. Everything that you hear on this call, there is not one surprise. Not one. Everything that we are delivering, we have told you we are going to deliver. Everything that we are focusing on are things that we have mentioned, if not recently, you know, a year or two ago. We are executing to our plan because there is a massive opportunity in digital ultrasound. We are digital to film, and we are digital that will take over analog. It is just a fait accompli. We have put a plan in place. We are executing to it. We have an awesome team. We are beyond the time where there was doubt about the company, and the only doubt should be in that, you know, for anyone who is in our way. I appreciate your attention, and I look forward to continuing to deliver results. Thank you.

Thank you, everyone. This concludes today's Butterfly Network, Inc. Q4 and FY 2025 earnings call. Thank you for joining. You may now disconnect your line.